Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxazosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MMP1 | P03956 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | TACR1 | P25103 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxazosin SCHEMBL30772126 | 1.00 | KMT2A (1.00) | KMT2AMMP1ADRB2CHRM2HTR1A | |
| Doxazosin SCHEMBL97513 | 1.00 | KMT2A (1.00) | KMT2AMMP1ADRB2CHRM2HTR1A | |
| Doxazosin SCHEMBL34111 | 1.00 | KMT2A (1.00) | KMT2AMMP1ADRB2CHRM2HTR1A | |
| Doxazosin SCHEMBL29711371 | 1.00 | KMT2A (1.00) | KMT2AMMP1ADRB2CHRM2HTR1A | |
| Doxazosin SCHEMBL29688095 | 1.00 | KMT2A (1.00) | KMT2AMMP1ADRB2CHRM2HTR1A | |
| Doxazosin SCHEMBL29641831 | 1.00 | KMT2A (1.00) | KMT2AMMP1ADRB2CHRM2HTR1A | |
| Doxazosin SCHEMBL8523145 | 0.99 | KMT2A (0.98) | KMT2AMMP1ADRB2CHRM2HTR1A | |
| Doxazosin SCHEMBL6479014 | 0.99 | KMT2A (0.98) | KMT2AMMP1ADRB2CHRM2HTR1A | |
| Doxazosin SCHEMBL612310 | 0.99 | KMT2A (0.98) | KMT2AMMP1ADRB2CHRM2HTR1A | |
| Doxazosin SCHEMBL5201447 | 0.97 | KMT2A (0.95) | KMT2AMMP1ADRB2CHRM2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1505981-B1 | UTILIZATION OF INHIBITORS OF EGFR-MEDIATED SIGNAL TRANSDUCTION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)/PROSTATIC HYPERTROPHY | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-07-11 | — | — | EP | claimed |
| US-20100144639-A1 | USE OF INHIBITORS OF THE EGFR-MEDIATED SIGNAL TRANSDUCTION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) / PROSTATIC HYPERTROPHY | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-10 | — | — | US | claimed |
| US-20070099918-A1 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-03 | — | — | US | claimed |
| US-20030225079-A1 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-04 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| CN-117597327-A | Pharmaceutical preparation | 第一波动生物制药股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023118074-A1 | COMPRESSIBLE AND FREE FLOWING CO-PROCESSED MESOPOROUS SILICA | UNIVERZA V LJUBLJANI (SI) | 2023-06-29 | — | — | WO | disclosed |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | FIRST WAVE BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| EP-0833937-B1 | OPTICAL RESOLUTION OF ALKYL 1,4-BENZODIOXAN-2-CARBOXYLATES USING ESTERASE FROM SERRATIA MARCESCENS | SEPRACOR INC (US) | 2002-01-23 | — | — | EP | disclosed |
| EP-0833937-B1 | OPTICAL RESOLUTION OF ALKYL 1,4-BENZODIOXAN-2-CARBOXYLATES USING ESTERASE FROM SERRATIA MARCESCENS | SEPRACOR INC (US) | 2002-01-23 | — | — | EP | disclosed |
| EP-0833937-A1 | OPTICAL RESOLUTION OF ALKYL 1,4-BENZODIOXAN-2-CARBOXYLATES USING ESTERASE FROM SERRATIA MARCESCENS | Seprachem, Inc. (US) | 1998-04-08 | — | — | EP | disclosed |
| EP-0833937-A1 | OPTICAL RESOLUTION OF ALKYL 1,4-BENZODIOXAN-2-CARBOXYLATES USING ESTERASE FROM SERRATIA MARCESCENS | Seprachem, Inc. (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1996040976-A1 | OPTICAL RESOLUTION OF ALKYL 1,4-BENZODIOXAN-2-CARBOXYLATES USING ESTERASE FROM SERRATIA MARCESCENS | SEPRACHEM, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040976-A1 | OPTICAL RESOLUTION OF ALKYL 1,4-BENZODIOXAN-2-CARBOXYLATES USING ESTERASE FROM SERRATIA MARCESCENS | SEPRACHEM, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5529929-A | USING AQUEOUS SOLUTION OF MICROBIAL ESTERASE | SEPRACHEM, INC. (US) | 1996-06-25 | — | — | US | disclosed |
| US-5529929-A | USING AQUEOUS SOLUTION OF MICROBIAL ESTERASE | SEPRACHEM, INC. (US) | 1996-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | ADRA1D 4593/4885ADRA1A 4557/4885ADRA1B 4659/4885 |
| US-20070099918-A1 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy | BPHL, EGFR, ERBB3 | ADRA1D 326/4885ADRA1A 356/4885ADRA1B 240/4885 |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | ACE2, ACE, MME | ADRA1D 3586/4885ADRA1A 2915/4885ADRA1B 3460/4885 |
| US-20100144639-A1 | USE OF INHIBITORS OF THE EGFR-MEDIATED SIGNAL TRANSDUCTION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) / PROSTATIC HYPERTROPHY | BPHL, EGFR, ERBB3 | ADRA1D 326/4885ADRA1A 356/4885ADRA1B 240/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | ADRA1D 3728/4885ADRA1A 3089/4885ADRA1B 3651/4885 |
| US-20230201143-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | ADRA1D 4170/4885ADRA1A 3619/4885ADRA1B 4075/4885 |
| US-20030225079-A1 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy | BPHL, EGFR, ERBB3 | ADRA1D 326/4885ADRA1A 356/4885ADRA1B 240/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | ADRA1D 4596/4885ADRA1A 4574/4885ADRA1B 4664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.